Results 51 to 60 of about 203,318 (355)

Variant constraint by mRNA vaccines [PDF]

Nature Reviews Immunology, 2021
The currently licensed mRNA vaccines for SARS-CoV-2 can elicit cross-neutralizing antibodies against B.1.351 variants of the virus, but are less potent against these variants.
openaire   +2 more sources

Neo-Antigen mRNA Vaccines [PDF]

Vaccines, 2020
The interest in therapeutic cancer vaccines has caught enormous attention in recent years due to several breakthroughs in cancer research, among which the finding that successful checkpoint blockade treatments reinvigorate neo-antigen-specific T cells and that successful adoptive cell therapies are directed towards neo-antigens. Neo-antigens are cancer-
Arthur Esprit, Wout de Mey, Rajendra Bahadur Shahi, Kris Thielemans, Lorenzo Franceschini, Karine Breckpot   +5 more
openaire   +4 more sources

Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle?

Reproductive Biology and Endocrinology, 2021
Objective No information exists in the literature regarding the effect of mRNA SARS-CoV-2 vaccine on subsequent IVF cycle attempt. We therefore aim to assess the influence of mRNA SARS-CoV-2 vaccine on IVF treatments.
Raoul Orvieto, Meirav Noach-Hirsh, Aliza Segev-Zahav, Jigal Haas, Ravit Nahum, Adva Aizer   +5 more
doaj   +1 more source

Leishmania tarentolae: taxonomic classification and its application as a promising biotechnological expression host

, 2019
In this review, we summarize the current knowledge concerning the eukaryotic protozoan parasite Leishmania tarentolae, with a main focus on its potential for biotechnological applications.
Klatt, S., Konthur, Z., Maslov, D., Simpson, L.   +3 more
core   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, Volume 20, Issue 6, Page 1643-1660, June 2026.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

COVID‐19 Vaccination Is Not Associated With the Development of Idiopathic Inflammatory Myositis in US Veterans

Arthritis Care &Research, EarlyView.
Objective Several case reports have proposed a potential association between COVID‐19 vaccination and the subsequent development of idiopathic inflammatory myositis (IIM). This study examined prior COVID‐19 vaccination in US veterans who developed new‐onset IIM compared to those without new‐onset IIM.
Caleb Hernández, Naomi Schlesinger, Jorge Rojas, Jessica A. Walsh, Tawnie J. Braaten, Gary A. Kunkel, Makoto Jones, Brian C Sauer, Julio Facelli, Grant W. Cannon, Dorota Lebiedz‐Odrobina   +10 more
wiley   +1 more source

The mRNA vaccine, a swift warhead against a moving infectious disease target

Expert Review of Vaccines
Introduction The rapid development of mRNA vaccines against SARS-CoV-2 has revolutionized vaccinology, offering hope for swift responses to emerging infectious diseases.
Sheema Mir, Mohammad Mir
doaj   +1 more source

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine

Clinical & Translational Immunology, 2022
Objective Despite the high vaccine efficacy of mRNA COVID‐19 vaccines, there are individuals who developed excessive reactogenic and/or allergic responses after the first mRNA dose and were considered ineligible for further mRNA doses.
Yun Shan Goh, Siew‐Wai Fong, Angeline Rouers, Zi Wei Chang, Matthew Zirui Tay, Jean‐Marc Chavatte, Nicole Ziyi Zhuo, Pei Xiang Hor, Chiew Yee Loh, Yuling Huang, Joel Xu En Wong, Yong Jie Tan, Daniel Rui Xiang Lim, Bei Wang, Eve Zi Xian Ngoh, Siti Nazihah Mohd Salleh, Raphael Tze Chuen Lee, Surinder Pada, Louisa Jin Sun, Desmond Luan Seng Ong, Jyoti Somani, Eng Sing Lee, NCID Study Group, COVID‐19 Study Group, Sebastian Maurer‐Stroh, Cheng‐I Wang, Yee‐Sin Leo, Raymond TP Lin, Ee Chee Ren, David C Lye, Barnaby Edward Young, Poh Lian Lim, Lisa FP Ng, Laurent Renia   +33 more
doaj   +1 more source

Biodistribution of mRNA COVID-19 vaccines in human breast milkResearch in context

EBioMedicine, 2023
Summary: Background: COVID-19 mRNA vaccines play a vital role in the fight against SARS-CoV-2 infection. However, lactating women have been largely excluded from most vaccine clinical trials.
Nazeeh Hanna, Claudia Manzano De Mejia, Ari Heffes-Doon, Xinhua Lin, Bishoy Botros, Ellen Gurzenda, Christie Clauss-Pascarelli, Amrita Nayak   +7 more
doaj   +1 more source

Biomimetic Nanovaccine Integrating Dendritic Cell Exosomes with Tumor Cell Membranes for Sustained Prophylaxis Against Glioblastoma

Advanced Functional Materials, EarlyView.
We have developed DEX/GM, an all‐natural, personalizable hybrid vaccine designed by coating dendritic cell‐derived exosomes (DEX) onto tumor cell membranes (GM) for sustained prophylaxis against glioblastoma (GBM). ABSTRACT Glioblastoma (GBM), one of the most aggressive and lethal brain tumors, remains incurable with a poor clinical prognosis.
Shanshan Li, Dongya Zhang, Shiyu Wang, Changhe Pang, Meng Zheng, Bingyang Shi, Yan Zou   +6 more
wiley   +1 more source